From Wikipedia, the free encyclopedia
Barbexaclone
Combination of
Phenobarbital Barbiturate
Levopropylhexedrine Sympathomimetic
Clinical data
AHFS/ Drugs.com International Drug Names
ATC code
Legal status
Legal status
Identifiers
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
CompTox Dashboard ( EPA)
ECHA InfoCard 100.022.278 Edit this at Wikidata
 ☒NcheckY  (what is this?)   (verify)

Barbexaclone (Maliasin) is a salt compound of phenobarbital and levopropylhexedrine. [2] It was introduced in 1983. It has been reported to be as effective as phenobarbital but better tolerated; however, as of 2004, these "promising results" [3] had not yet been confirmed nor denied in controlled trials.

Potency

100 mg of barbexaclone is equivalent to 60 mg of phenobarbital. [2]

References

  1. ^ Anvisa (2023-03-31). "RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial" [Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control] (in Brazilian Portuguese). Diário Oficial da União (published 2023-04-04). Archived from the original on 2023-08-03. Retrieved 2023-08-16.
  2. ^ a b Shorvon S, Perucca E, Engel Jr J (23 September 2015). The Treatment of Epilepsy. Wiley. pp. 1706–1707. ISBN  978-1-118-93699-3.
  3. ^ Salles Barbosa MF (September 1978). "[Barbexaclone in the treatment of cerebral dysrhythmia]". Arquivos de Neuro-Psiquiatria. 36 (3): 245–249. doi: 10.1590/s0004-282x1978000300009. PMID  28716.

Further reading

Stub icon

This sedative-related article is a stub. You can help Wikipedia by expanding it.

Retrieved from " https://en.wikipedia.org/?title=Barbexaclone&oldid=1201481461"